Response to Letter to the Editor

J Thorac Oncol. 2021 May;16(5):e30-e31. doi: 10.1016/j.jtho.2021.02.018.

Authors

Makoto Nishio¹, Diana Mendus², Lijia Wang², Mark A Socinski³

Affiliations

¹ Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: [email protected].
² Genentech, Inc, South San Francisco, California.
³ Department of Medical Oncology, AdventHealth Cancer Institute, Orlando, Florida.

PMID: 33896576
DOI: 10.1016/j.jtho.2021.02.018

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Lung Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
atezolizumab